^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CaspaCIDe DLI (rimiducid activated rivogenlecleucel)
i
Other names: BPX-501, BPX 501, donor lymphocyte infusion with donor T cells containing retrovirus-delivered CaspaCIDe safety switch, T cells transduced with CaspaCIDe suicide gene, BPX-501 T cell infusion, rimiducid activated BPX 501, BPX-501-rimiducid, BPX-501/AP1903, BPX-501-AP1903
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Bellicum
Drug class:
Immunomodulator, Cell replacement
Related drugs:
8ms
Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases (clinicaltrials.gov)
P1, N=1, Terminated, Bellicum Pharmaceuticals | Active, not recruiting --> Terminated; due to lack of enrollment and changes to the sponsor development portfolio
Trial termination
|
CD34 (CD34 molecule) • HLA-B (Major Histocompatibility Complex, Class I, B)
|
CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)
1year
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant (clinicaltrials.gov)
P1/2, N=187, Terminated, Bellicum Pharmaceuticals | Active, not recruiting --> Terminated; Sponsor decision
Trial termination
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
|
CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)
over1year
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies (clinicaltrials.gov)
P1/2, N=44, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Mar 2023 | Trial primary completion date: Jun 2023 --> Mar 2023
Trial completion • Trial completion date • Trial primary completion date
|
IL15 (Interleukin 15)
|
cyclophosphamide • fludarabine IV • mesna • CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)
almost2years
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant (clinicaltrials.gov)
P1/2, N=187, Active, not recruiting, Bellicum Pharmaceuticals | Phase classification: P2 --> P1/2
Phase classification
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
|
CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)
over2years
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies (clinicaltrials.gov)
P1/2, N=36, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2022 --> Jun 2024 | Trial primary completion date: Jun 2022 --> Jun 2023
Trial completion date • Trial primary completion date
|
CD19 (CD19 Molecule) • IL15 (Interleukin 15)
|
cyclophosphamide • fludarabine IV • mesna • CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)
4years
Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant (clinicaltrials.gov)
P2, N=193, Active, not recruiting, Bellicum Pharmaceuticals | Trial completion date: Dec 2021 --> Feb 2033
Clinical • Trial completion date
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD4 (CD4 Molecule)
|
CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)
4years
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant (clinicaltrials.gov)
P1/2, N=36, Active, not recruiting, Bellicum Pharmaceuticals | Trial completion date: Dec 2033 --> Nov 2032
Clinical • Trial completion date
|
FLT3 (Fms-related tyrosine kinase 3) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
|
MLL rearrangement • MLL rearrangement
|
CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)
4years
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant (clinicaltrials.gov)
P1, N=10, Active, not recruiting, Bellicum Pharmaceuticals | Trial completion date: Dec 2034 --> Jan 2033 | Trial primary completion date: Mar 2018 --> Jan 2020
Clinical • Trial completion date • Trial primary completion date • Minimal residual disease
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
|
CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)
4years
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant (clinicaltrials.gov)
P1/2, N=120, Active, not recruiting, Bellicum Pharmaceuticals | Phase classification: P2 --> P1/2 | Trial completion date: Feb 2035 --> May 2034 | Trial primary completion date: Feb 2020 --> May 2021
Clinical • Phase classification • Trial completion date • Trial primary completion date
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
|
CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)
4years
Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant (clinicaltrials.gov)
P1, N=15, Active, not recruiting, Bellicum Pharmaceuticals | Recruiting --> Active, not recruiting | Trial completion date: Mar 2035 --> Jul 2035 | Trial primary completion date: Mar 2020 --> Jul 2022
Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Minimal residual disease
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
|
CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)
almost6years
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant (clinicaltrials.gov)
P1; N=30; Not yet recruiting; Sponsor:University of Washington
New P1 trial • Clinical
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
|
MLL rearrangement
|
CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)
Share via
